Related Experiment Video
Updated: Aug 17, 2026
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Risk-stratified MRI surveillance for hepatocellular carcinoma in cirrhosis: a prospective cohort study
Byeong Geun Song1, Woo Kyoung Jeong2, Myung Ji Goh1
1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Objectives:
Current hepatocellular carcinoma (HCC) surveillance relies on semiannual ultrasonography, which has limited sensitivity for early-stage detection. We evaluated the effectiveness of HCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals in patients with cirrhosis.
Materials And Methods:
We prospectively enrolled 86 patients with cirrhosis between May 2021 and October 2022. All patients underwent HCC surveillance using gadoxetic acid-enhanced MRI for 3 years at risk-stratified screening intervals ranging from 3 to 36 months, according to the assigned risk category defined by LI-RADS criteria on baseline MRI (low, intermediate, and high risk with LI-RADS LR-3 or LR-4 observations). The primary outcome was surveillance failure, defined as the detection of HCC beyond the Milan criteria.
Results:
HCC was diagnosed in 13 patients during the study period. The HCC incidence differed markedly across the MRI risk categories, ranging from 1.9 per 100 person-years in patients with low risk to 73.4 per 100 person-years in those with LR-4 observations. The primary endpoint was met with no surveillance failures (0%; 95% CI: 0-24.7%). Ten cases (76.9%) were identified at a very early stage, and there was one interval cancer (7.7%). Compared to a uniform semiannual surveillance strategy, the risk-stratified approach reduced the number of surveillance examinations by 44.2%.
Conclusion:
HCC surveillance using gadoxetic acid-enhanced MRI at risk-stratified screening intervals resulted in no surveillance failures, a high rate of early-stage tumor detection, and a low incidence of interval cancer. This approach may improve surveillance effectiveness while reducing examination frequency.
Key Points:
QuestionWhether risk-stratified surveillance intervals for gadoxetic acid-enhanced MRI can maintain early HCC detection while reducing examination burden in cirrhosis remains unknown. FindingsRisk-stratified MRI surveillance detected all 13 incident HCCs within Milan criteria, with zero surveillance failures and a 44.2% reduction in examinations. Clinical relevanceRisk-stratified gadoxetic acid-enhanced MRI surveillance enables personalized screening intervals based on imaging risk categories, maintaining early-stage HCC detection while substantially reducing examination frequency in patients with cirrhosis.